Centanafadine

Centanafadine is under investigation in clinical trial NCT02827513 (A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects).

Title	Posted	Study ID	Phase	Status	Sponsor
A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety	2025/05/15	NCT06973577	Phase 3	Recruiting	Otsuka Pharmaceutical Development & Commercialization, Inc.
Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder	2022/09/10	NCT05536414	Phase 2	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)	2022/06/22	NCT05428033	Phase 3	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)	2022/03/15	NCT05279313	Phase 3	Active, not recruiting	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder	2022/02/25	NCT05257265	Phase 3	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder	2021/11/09	NCT05113953	Phase 2	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment	2021/10/04	NCT05066724	Phase 2	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder	2021/03/08	NCT04786730	Phase 1	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder	2020/05/21	NCT04398225	Phase 1	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.
Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules in Pediatric Participants With Attention-deficit Hyperactivity Disorder (ADHD)	2019/09/09	NCT04081363	Phase 2	Completed	Otsuka Pharmaceutical Development & Commercialization, Inc.

Title

Posted

Study ID

Phase

Status

Sponsor

A Trial of Centanafadine Efficacy and Safety in Adults With Attention-deficit/Hyperactivity Disorder and Comorbid Anxiety

2025/05/15

NCT06973577

Phase 3

Recruiting

Otsuka Pharmaceutical Development & Commercialization, Inc.